The TIDE score, which evaluates tumor immune dysfunction and exclusion, is significantly higher in the MYO19-high group compared to the MYO19-low and normal groups (Kruskal-Wallis test, p < 0.001). The gene discussed is MYO19; the disease is neoplasm.